Literature DB >> 508495

Increased carbon dioxide production in two patients with malignant hyperpyrexia and its control by dantolene.

F Liebenschütz, C Mai, V W Pickerodt.   

Abstract

Two patients with successfully treated malignant hyperpyrexia are reported. Carbon dioxide output, calculated from the respiratory minute volume and PaCO2, was found to be greatly increased in both patients. In the patient who received dantolene 7.5 mg kg-1 the carbon dioxide output decreased rapidly to normal values, whereas in the other patient carbon dioxide output remained increased for several hours.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 508495     DOI： 10.1093/bja/51.9.899

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


  6 in total

1.  End-tidal carbon dioxide concentration, carbon dioxide production, heart rate, and blood pressure as indicators of induced hyperthermia.

Authors:  V de las Alas; W D Voorhees; L A Geddes; J D Bourland; W E Schoenlein
Journal:  J Clin Monit       Date:  1990-07

2.  Treatment of porcine malignant hyperthermia: lactate gradient from muscle to blood.

Authors:  G A Gronert; C P Ahern; J H Milde
Journal:  Can Anaesth Soc J       Date:  1986-11

3.  The anaesthetic management of the malignant hyperthermia susceptible parturient.

Authors:  M J Douglas; G H McMorland
Journal:  Can Anaesth Soc J       Date:  1986-05

Review 4.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

Review 5.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

6.  Anaesthesia for caesarean delivery of a malignant hyperthermia susceptible parturient.

Authors:  S J Lucy
Journal:  Can J Anaesth       Date:  1994-12       Impact factor: 5.063
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.